# Aficamten

Drug · id `cardio:aficamten` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Myqorzo

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Aficamten is the medicine in Myqorzo, a tablet. The US label calls it a cardiac myosin inhibitor, and says it is an allosteric and reversible inhibitor of cardiac myosin motor activity. The label gives its indication as symptomatic obstructive hypertrophic cardiomyopathy in adults, to improve functional capacity and symptoms. A boxed warning says it reduces left ventricular ejection fraction and can cause heart failure, and that it is available only through a restricted program. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 2731469; the label UNII B1I77MH6K1 equals the ingredient's. MeSH has no descriptor for aficamten (an exact-label lookup returned an empty list on 2026-11-19). RxClass returned no FDA class for the ingredient (empty answer, hash only), so the class wording comes from the label, which calls the product a cardiac myosin inhibitor; RxClass gives mavacamten the established pharmacologic class Cardiac Myosin Inhibitor. The atlas has no page for that class, so the record files under the medicines front and links to mavacamten. The label read is the Cytokinetics Inc. label for Myqorzo, application NDA219083, effective 2025-12-16 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with four tablet strengths. This page records the label indication, the boxed-warning title and two statements, and the mechanism sentence only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients treated with aficamten, as described in a US Myqorzo label boxed warning about heart failure

Recipient: Recipient not specified; Population: Patients who take the medicine, as the boxed warning describes the risk: the warning concerns heart failure due to systolic dysfunction in people treated with it. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning titled risk of heart failure. It says the medicine "reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction", and that, because of this risk, it "is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)".

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients who take the medicine, as the boxed warning describes the risk: the warning concerns heart failure due to systolic dysfunction in people treated with it. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning title and two statements only. The warning also gives instructions about heart-ultrasound checks, ejection-fraction thresholds and stopping or changing treatment; those are the label's, are not repeated here and are not advice. Other warnings, contraindications and interactions were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Application number of the label read, NDA219083.
  2. Background: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Effective date of the label text read, 20251216.
  3. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-08).
  4. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first sentence. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-09).
  5. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], restricted program sentence. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-10).

## Context: Adults with symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Myqorzo

Recipient: Recipient not specified; Population: Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Myqorzo (aficamten tablets; Cytokinetics Inc., application NDA219083; the version dated 2025-12-16 in openFDA) calls the product a cardiac myosin inhibitor. It lists the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms, as the indication.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning, recorded in a separate claim. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Application number of the label read, NDA219083.
  2. Background: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Effective date of the label text read, 20251216.
  3. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], highlights sentence. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-04).
  4. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indication statement. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-05).
  5. Supports: openFDA drug label record for aficamten tablets (Myqorzo), Cytokinetics Inc. label: indications, mechanism, boxed warning (Regulator, edition The openFDA drug label record for set id fd778507-1274-4d1a-a659-5431d55c543a (manufacturer Cytokinetics Inc., application NDA219083), returned on 2026-11-19. The label text is dated 2025-12-16 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22fd778507-1274-4d1a-a659-5431d55c543a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indication statement, purpose. Retrieved 2026-11-19T00:29:55Z. Source state: Current. Version fingerprint: f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-AFI-LB-06).

## Connected pages

- FDA label lists symptomatic obstructive hypertrophic cardiomyopathy in adults, to improve functional capacity and symptoms, as an indication: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-fda-myqorzo-label-indications` and its context]
- The Myqorzo label calls aficamten a cardiac myosin inhibitor, and RxClass gives mavacamten the FDA established class Cardiac Myosin Inhibitor: Mavacamten (`cardio:mavacamten`)
- The label's boxed warning says the medicine reduces left ventricular ejection fraction and can lead to heart failure from systolic dysfunction: Heart failure (`cardio:heart-failure`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: ea828d1641110e5cc6efeb1025faaa6af4c40716bdd42b15b4790e92981f53c6
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
